Celgene Corporation (NASDAQ:CELG) was the recipient of unusually large options trading activity on Thursday. Stock traders bought 9,159 put options on the company. This is an increase of 162% compared to the typical volume of 3,491 put options.

In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 253,761 shares of company stock valued at $33,792,445. Company insiders own 0.95% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in CELG. BlackRock Inc. increased its stake in Celgene Corporation by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. increased its stake in Celgene Corporation by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. State Street Corp increased its stake in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Jennison Associates LLC increased its stake in Celgene Corporation by 1.2% in the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock worth $1,742,301,000 after buying an additional 156,864 shares during the last quarter. Finally, FMR LLC increased its stake in Celgene Corporation by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after buying an additional 697,250 shares during the last quarter. Institutional investors own 79.43% of the company’s stock.

A number of equities analysts have commented on the stock. Jefferies Group LLC set a $154.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a research report on Tuesday, August 29th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have given a buy rating to the company. Celgene Corporation currently has a consensus rating of “Buy” and an average price target of $147.38.

Celgene Corporation (CELG) opened at 139.38 on Friday. The stock has a 50 day moving average price of $133.73 and a 200 day moving average price of $126.08. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $140.25. The firm has a market cap of $109.04 billion, a P/E ratio of 43.17 and a beta of 1.88.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS. On average, analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/03/celgene-corporation-sees-unusually-high-options-volume-celg.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.